Lancet Diabetes Endocrinol (2022) 10(3):193206
, Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial, Lancet Diabetes Endocrinol
Both compounds have become widely recognised within scientific and research communities due to their unique biological characteristics and the growing body of literature surrounding their mechanisms of action
STORAGE Lyophilized 4 C 24 months Reconstituted 28 C, 28 days PEER-REVIEWED EVIDENCE Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B
Semaglutide reshapes your relationship with food by naturally reducing cravings for high-reward foods, but refined sugars can interfere with this neurochemical benefit
Direct medical cost of diabetes in rural China using electronic insurance claims data and diabetes management data